Skip to main content

Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.

Publication ,  Journal Article
McDonough, CW; Gillis, NK; Alsultan, A; Chang, S-W; Kawaguchi-Suzuki, M; Lang, JE; Shahin, MHA; Buford, TW; El Rouby, NM; Sá, ACC; Langaee, TY ...
Published in: PLoS One
2013

We sought to identify novel pharmacogenomic markers for HDL-C response to atenolol in participants with mild to moderate hypertension. We genotyped 768 hypertensive participants from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study on the Illumina HumanCVD Beadchip. During PEAR, participants were randomized to receive atenolol or hydrochlorothiazide. Blood pressure and cholesterol levels were evaluated at baseline and after treatment. This study focused on participants treated with atenolol monotherapy. Association with atenolol induced HDL-C change was evaluated in 232 whites and 152 African Americans using linear regression. No SNPs achieved a Bonferroni corrected P-value. However, we identified 13 regions with consistent association across whites and African Americans. The most interesting of these regions were seven with prior associations with HDL-C, other metabolic traits, or functional implications in the lipid pathway: GALNT2, FTO, ABCB1, LRP5, STARD3NL, ESR1, and LIPC. Examples are rs2144300 in GALNT2 in whites (P=2.29x10(-4), β=-1.85 mg/dL) and rs12595985 in FTO in African Americans (P=2.90x10(-4), β=4.52 mg/dL), both with consistent regional association (P<0.05) in the other race group. Additionally, baseline GALNT2 expression differed by rs2144300 genotype in whites (P=0.0279). In conclusion, we identified multiple gene regions associated with atenolol induced HDL-C change that were consistent across race groups, several with functional implications or prior associations with HDL-C.

Duke Scholars

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2013

Volume

8

Issue

10

Start / End Page

e76984

Location

United States

Related Subject Headings

  • White People
  • Proteins
  • Polypeptide N-acetylgalactosaminyltransferase
  • Polymorphism, Single Nucleotide
  • Pharmacogenetics
  • N-Acetylgalactosaminyltransferases
  • Middle Aged
  • Membrane Proteins
  • Male
  • Low Density Lipoprotein Receptor-Related Protein-5
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McDonough, C. W., Gillis, N. K., Alsultan, A., Chang, S.-W., Kawaguchi-Suzuki, M., Lang, J. E., … Johnson, J. A. (2013). Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One, 8(10), e76984. https://doi.org/10.1371/journal.pone.0076984
McDonough, Caitrin W., Nancy K. Gillis, Abdullah Alsultan, Shin-Wen Chang, Marina Kawaguchi-Suzuki, Jason E. Lang, Mohamed Hossam A. Shahin, et al. “Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.PLoS One 8, no. 10 (2013): e76984. https://doi.org/10.1371/journal.pone.0076984.
McDonough CW, Gillis NK, Alsultan A, Chang S-W, Kawaguchi-Suzuki M, Lang JE, et al. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One. 2013;8(10):e76984.
McDonough, Caitrin W., et al. “Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.PLoS One, vol. 8, no. 10, 2013, p. e76984. Pubmed, doi:10.1371/journal.pone.0076984.
McDonough CW, Gillis NK, Alsultan A, Chang S-W, Kawaguchi-Suzuki M, Lang JE, Shahin MHA, Buford TW, El Rouby NM, Sá ACC, Langaee TY, Gums JG, Chapman AB, Cooper-DeHoff RM, Turner ST, Gong Y, Johnson JA. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One. 2013;8(10):e76984.

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2013

Volume

8

Issue

10

Start / End Page

e76984

Location

United States

Related Subject Headings

  • White People
  • Proteins
  • Polypeptide N-acetylgalactosaminyltransferase
  • Polymorphism, Single Nucleotide
  • Pharmacogenetics
  • N-Acetylgalactosaminyltransferases
  • Middle Aged
  • Membrane Proteins
  • Male
  • Low Density Lipoprotein Receptor-Related Protein-5